Susquehanna Fundamental Investments LLC Acquires New Shares in Emergent BioSolutions Inc. (NYSE:EBS)

Susquehanna Fundamental Investments LLC acquired a new stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 98,731 shares of the biopharmaceutical company's stock, valued at approximately $944,000. Susquehanna Fundamental Investments LLC owned 0.18% of Emergent BioSolutions at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in EBS. Barclays PLC raised its position in Emergent BioSolutions by 361.6% in the third quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company's stock worth $329,000 after acquiring an additional 30,792 shares during the period. Geode Capital Management LLC boosted its position in Emergent BioSolutions by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company's stock valued at $4,861,000 after buying an additional 25,776 shares during the period. B. Riley Wealth Advisors Inc. purchased a new position in shares of Emergent BioSolutions in the third quarter worth $295,000. Assenagon Asset Management S.A. raised its position in shares of Emergent BioSolutions by 3.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company's stock worth $7,328,000 after purchasing an additional 24,985 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in Emergent BioSolutions during the fourth quarter worth about $1,831,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

EBS has been the subject of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday, April 1st. StockNews.com cut Emergent BioSolutions from a "buy" rating to a "hold" rating in a research report on Wednesday, March 5th.

Emergent BioSolutions Stock Performance

EBS stock traded up $1.37 during mid-day trading on Thursday, hitting $6.11. The company had a trading volume of 2,042,803 shares, compared to its average volume of 1,918,695. The stock's fifty day moving average price is $5.16 and its two-hundred day moving average price is $7.96. Emergent BioSolutions Inc. has a 12 month low of $4.02 and a 12 month high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The firm has a market cap of $332.00 million, a PE ratio of -1.49 and a beta of 2.09.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.22. The business had revenue of $222.20 million during the quarter, compared to analysts' expectations of $218.50 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. On average, analysts forecast that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent BioSolutions declared that its Board of Directors has authorized a stock repurchase program on Monday, March 31st that permits the company to repurchase $50.00 million in outstanding shares. This repurchase authorization permits the biopharmaceutical company to repurchase up to 19% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's board of directors believes its stock is undervalued.

Insider Activity at Emergent BioSolutions

In related news, Director Neal Franklin Fowler sold 35,000 shares of Emergent BioSolutions stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total transaction of $204,050.00. Following the completion of the transaction, the director now directly owns 101,100 shares of the company's stock, valued at approximately $589,413. The trade was a 25.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 1.20% of the stock is owned by company insiders.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.